Core Viewpoint - The article highlights the rapid IPO of Zhonghui Biotech, which achieved a listing on the Hong Kong Stock Exchange in just 10 months, setting a record for the fastest project handled by intermediary institutions [2][4]. Company Overview - Zhonghui Biotech, founded by An Youcai, is a newcomer in the vaccine industry, having been established only 10 years ago and currently offering one vaccine on the market [2][6]. - The company’s flu vaccine is the only quadrivalent subunit vaccine available in the domestic market, priced at 319 yuan per dose, making it the most expensive flu vaccine in China [10][11]. Financial Aspects - The IPO raised approximately 383 million HKD, which will alleviate the company's financial pressure, especially as it faces a bank loan repayment of about 400 million yuan within a year [4]. - As of the end of Q1 2025, Zhonghui Biotech had a cash balance of only 115 million yuan [4]. Market Position and Strategy - Zhonghui Biotech aims to position itself as an international company focused on innovation in the vaccine sector, distinguishing itself from competitors by not participating in the price-cutting trend for flu vaccines [3][10]. - The company is expanding its market reach internationally, particularly targeting Southeast Asia and Latin America, and has formed a strategic partnership with Watson Bio for overseas sales [11]. Product Development - Currently, Zhonghui Biotech has 11 vaccines in its pipeline, with 10 in development and one already on the market [10]. - The company is also working on a human diploid rabies vaccine and other products aimed at replacing imported vaccines and leading globally in vaccine technology [12][13]. Leadership and Expertise - An Youcai, the founder, transitioned into the vaccine industry from a non-biological background, leveraging 15 years of entrepreneurial experience to enhance his expertise in immunology and vaccine development [6][8]. - The company has attracted experienced scientists to its team, including those who have previously worked on significant vaccine projects [7].

Group 1: Company Strategy and Development - The company focuses on "endogenous innovation + external expansion" to enhance international business and strengthen domestic market promotion [2][3] - Key products include human diploid rabies vaccine, 13-valent pneumonia vaccine, hepatitis B vaccine, and varicella vaccine, with ongoing efforts to promote and sell these products [2][3] - The company aims to build a diversified growth engine by exploring new business areas aligned with its strategic development [3] Group 2: Product Development and Sales - The freeze-dried human rabies vaccine, the first of its kind in China, achieved sales revenue of CNY 337 million in 2024 after being approved in April 2024 [4] - The five-component vaccine is currently in Phase I clinical trials, with plans to advance to Phase III upon completion [5] - The 13-valent pneumonia vaccine has low domestic penetration but significant future growth potential, with ongoing international collaborations for registration and sales [6][7] Group 3: Research and Development Investment - In 2024, the company invested CNY 569 million in R&D, accounting for 21.47% of its annual revenue, with a cumulative investment of CNY 2.105 billion over the past three years [8] - The company has over 30 projects in the pipeline, with 18 projects entering the registration process [8] - The company is also focusing on innovative vaccine technologies, including mRNA and viral vector technologies [9] Group 4: Financial Performance and Shareholder Returns - In 2024, the company distributed cash dividends of CNY 101 million, representing 49.85% of the net profit attributable to shareholders [13] - Since its listing in 2017, the company has cumulatively distributed CNY 1.885 billion in cash dividends, accounting for 45.06% of the total net profit [13] Group 5: International Expansion and Partnerships - The company is actively pursuing international markets in Southeast Asia, South Asia, the Middle East, and other regions, with multiple agreements for vaccine registration and commercialization [12] - A strategic partnership with AstraZeneca aims to establish a joint venture for vaccine development in China, enhancing the company's international presence [11]